Alibaba Health Information Technology (HK:0241) has released an update.
Alibaba Health Information Technology Limited reported a robust financial performance for the six months ending September 30, 2024, with a notable 10.2% increase in revenue to RMB14.27 billion and a 72.8% surge in net profit. The company saw significant growth in its Taobao and Tmall Healthcare Platform, serving over 300 million consumers and enhancing its pharmaceutical e-commerce platform revenue by 67.5%. Despite a dip in healthcare and digital services revenue, Alibaba Health expanded its direct sales business and continued to innovate in drug tracking and online healthcare services.
For further insights into HK:0241 stock, check out TipRanks’ Stock Analysis page.
